Media & Press

FOR IMMEDIATE RELEASE [Covington, KY---June 13, 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company, announced today that two abstracts submitted for an in-person session at the IPSNO annual meeting to be held in Hamburg, Germany, June 12-15, 2022 has been chosen for poster presentation. ISPNO is the largest international scientific meeting of multidisciplinary professionals ... Read More

Seasoned BIO/Pharma Executive adds finance, strategic capital access and public market readiness to the management team FOR IMMEDIATE RELEASE [Covington, KY---June 2, 2022l] Bexion Pharmaceuticals, Inc., a mid-stage biopharmaceutical company developing innovative therapies for cancers and chemotherapy induced peripheral neuropathy (CIPN), announced today that Ms. Joyce LaViscount has joined the Company’s leadership team as Chief ... Read More

FOR IMMEDIATE RELEASE [Covington, KY---May 10, 2022 ] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for the CIMT annual meeting to be held in Mainz, Germany, May 10-12, 2022 has been chosen for poster presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the ... Read More

The new leadership roles support the company’s momentum in becoming the leader in developing and commercializing therapeutics based on exploiting the lysosome to treat challenging solid tumors as well as chemotherapy-induced peripheral neuropathy (CIPN). FOR IMMEDIATE RELEASE [Covington, KY---February 2, 2022] Bexion Pharmaceuticals, a clinical stage biopharmaceutical company, today announced key leadership changes, including the ... Read More

Covington, KY, December 23, 2021 – Bexion Pharmaceuticals, Inc, today announced that it is presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation. This year, registered attendees to Biotech Showcase can access Bexion’s recorded company presentation beginning the week of December 6th – five weeks prior to the actual event. 24x7 on-demand ... Read More

FOR IMMEDIATE RELEASE Covington, KY,  29 September 2021               Bexion Pharmaceuticals, Inc. announced today that a Study May Proceed letter has been received from the US Food and Drug Administration (FDA) for the Investigational New Drug Application (IND) for BXQ-350 to initiate a Phase 1b/2 clinical trial in newly diagnosed stage 4 metastatic colorectal cancer patients. ... Read More

FOR IMMEDIATE RELEASE [Covington, KY---September 17, 2021] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that Gilles Tapolsky PhD, MBA, Bexion’s Vice President, Pharmacology will be virtually presenting preclinical and clinical data of the Company’s lead compound, BXQ-350.  The presentation will be made at the Discovery on Target (DOT) Conference in the Immunology and ... Read More

FOR IMMEDIATE RELEASE [Covington, KY---April 20, 2021] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the ... Read More

Jupiter, FL— The award-winning series, Advancements with Ted Danson, will focus on an innovative, targeted approach to treating a range of diseases during 3Q/2021. Check local listings for more information. The diseases for which medicine offers few effective options – advanced cancer (or even early-stage cancer for certain types), neurodegenerative diseases and autoimmune diseases – persist because ... Read More

FOR IMMEDIATE RELEASE Covington, KY February 22, 2021 Bexion Pharmaceuticals, Inc. announced today that it has added Olivia F. Kirtley to its Board of Directors. Ms. Kirtley, a Certified Public Accountant and Chartered Global Management Accountant, is a business consultant on strategic, risk and corporate governance issues. She brings to Bexion extensive experience as ... Read More